Carlsmed Q2 revenue rises 57%, raises 2026 revenue forecast

Carlsmed

05/08/2026 21:15

Overview
US medical device maker's Q2 revenue rose 57% yr/yr on strong spine procedure demand
Company raised full-year 2026 revenue outlook to $74 mln-$78 mln, over 50% growth at midpoint
Q2 net loss and adjusted EBITDA loss widened as operating expenses increased

Outlook
Carlsmed raises 2026 revenue guidance to $74 mln-$78 mln from $72 mln-$77 mln
Company expects over 50% revenue growth in 2026 at midpoint of guidance range
Carlsmed says new CMS reimbursement for lumbar procedure expected to support ongoing growth

Result Drivers
SURGEON ADOPTION - Co said trained surgeon user base grew over 60% yr/yr, supporting increased procedure volumes
PROCEDURE VOLUME - Co reported strong volume growth across lumbar and cervical aprevo procedures, aided by digital production system scalability
CMS REIMBURSEMENT - Co expects recent CMS ruling with new reimbursement codes for aprevo lumbar procedure to expand access and support ongoing growth

Company press release: ID:nGNX8307ww

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$18.90 mln
 
Q2 Net Loss
 
$10.50 mln
 
Q2 Adjusted EBITDA
 
-$8.60 mln
 
Q2 Gross Margin
 
76.80%
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Carlsmed, Inc. is $18.00, about 34% above its August 4 closing price of $13.43

Reuters Recommended Reads
Aug 4 - Alphatec Q2 revenue beats estimates on strong surgical case volume
Aug 5 - Orthofix Medical Q2 sales slightly beat estimates
Aug 5 - Zimmer Biomet tops quarterly estimates, lifts profit forecast on strong implant demand

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)